Key observations from the NHLBI Asthma Clinical Research Network
Open Access
- 17 April 2012
- Vol. 67 (5), 450-455
- https://doi.org/10.1136/thoraxjnl-2012-201876
Abstract
The National Heart, Lung and Blood Institute (NHLBI) Asthma Clinical Research Network (ACRN) recently completed its work after 20 years of collaboration as a multicentre clinical trial network. When formed, its stated mission was to perform multiple controlled clinical trials for treating patients with asthma by dispassionately examining new and existing therapies, and to rapidly communicate its findings to the medical community. The ACRN conducted 15 major clinical trials. In addition, clinical data, manual of operations, protocols and template informed consents from all ACRN trials are available via NHLBI BioLINCC (https://biolincc.nhlbi.nih.gov/studies/). This network contributed major insights into the use of inhaled corticosteroids, short-acting and long-acting ß-adrenergic agonists, leukotriene receptor antagonists, and novel agents (tiotropium, colchicine and macrolide antibiotics). They also pioneered studies of the variability in drug response, predictors of treatment response and pharmacogenetics. This review highlights the major research observations from the ACRN that have impacted the current management of asthma.Keywords
This publication has 22 references indexed in Scilit:
- Safe use of long-acting β-agonists: what have we learnt?Expert Opinion on Drug Safety, 2011
- Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled AsthmaNew England Journal of Medicine, 2010
- A trial of clarithromycin for the treatment of suboptimally controlled asthmaJournal of Allergy and Clinical Immunology, 2010
- GSNO reductase and β2-adrenergic receptor gene–gene interaction: bronchodilator responsiveness to albuterolPharmacogenetics and Genomics, 2010
- Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trialThe Lancet, 2009
- Genetic variants of GSNOR and ADRB2 influence response to albuterol in African‐American children with severe asthmaPediatric Pulmonology, 2009
- Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studiesThe Lancet, 2007
- Systemic Effect Comparisons of Six Inhaled Corticosteroid PreparationsAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Significant variability in response to inhaled corticosteroids for persistent asthmaJournal of Allergy and Clinical Immunology, 2002
- Long-Acting β2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent AsthmaA Randomized Controlled TrialJAMA, 2001